TrialInvestigational new drugs2019

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Kenichi Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.